E-DRUG: NYT: 4 Diabetes Drugs Are Seen Raising Hope and Profit
--------------------------------------------------
[The moderators cannot judge whether the new drugs are better, but Exubera is the first heat stable insulin, and it avoids injections which are both advantages for developing countries. We are likely to have to discuss the price tag, and demand special, lower prices for developing countries.]
Re: Byetta, Exubera, Galvus and Januvia. Does anyone have any thoughts on the importance of promoting access to these diabetes medicines in developing countries? Jamie
http://www.nytimes.com/2006/06/22/business/22diabetes.html
The New York Times
June 22, 2006
4 Diabetes Drugs Are Seen Raising Hope and Profit
By ALEX BERENSON
Even as diabetes rates reach epidemic levels worldwide, four new
drugs are generating optimism among doctors as well as Wall Street
analysts.
New drugs alone will not reverse rising rates of Type 2 diabetes, a
condition that affects about 20 million Americans and is closely tied
to obesity and lack of physical activity. And doctors caution that
for the foreseeable future, diabetes will remain a progressively
worsening disease that can cause devastating complications.
But doctors say the new drugs are important additions to the
treatment arsenal because they work differently from existing
diabetes medicines and have relatively mild side effects.
With the annual market for diabetes drugs expected to reach at least
$25 billion worldwide by 2011, up from $15 billion today, drug makers
have been investing heavily in new approaches to treating diabetes.
And data presented at the American Diabetes Association's annual
scientific conference last week suggested they are having at least
some success.
One of the four treatments, Byetta, given by injection, is already on
the market. Another, Exubera, an inhalable form of insulin, has been
approved and will reach pharmacies next month. The other two, Galvus
and Januvia, both taken as pills, are awaiting approval from the Food
and Drug Administration, which analysts expect by early next year.
"There's cause for tremendous optimism," said Dr. John Buse, the
director of the diabetes center at the University of North Carolina
School of Medicine and the vice president of the American Diabetes
Association. "We have the drugs to basically control diabetes in 90
percent-plus of patients." Dr. Buse said he had consulted for the
manufacturers of all the new drugs.
Byetta, introduced in June 2005, has stirred especially high hopes.
The drug causes significant weight loss in many patients — in
contrast to most existing diabetes treatments, which cause weight
gain that can potentially worsen the disease. In addition, some data
in animal studies hints that Byetta may help the pancreas regrow the
cells that produce insulin, a crucial process in slowing the course
of diabetes.
Byetta has become so popular that its makers, Amylin Pharmaceuticals
and Eli Lilly, are having trouble meeting demand for it. Last week,
the companies began asking doctors not to start patients on Byetta
until a new manufacturing plant goes into operation, a process that
may take several months.
Analysts are optimistic about the commercial prospects of all four of
the drugs, forecasting that they will become blockbusters, with more
than $1 billion in worldwide sales each.
The new drugs will probably cost $1,500 to $2,000 a year per patient,
more than existing treatments, analysts say. Still, Byetta, won
coverage relatively easily from most insurers, and Galvus and Januvia
will probably follow because the complications of diabetes are so
expensive, making drug treatment relatively cost-effective, said
Richard Evans, an analyst at the Sanford C. Bernstein & Company
investment bank.
Mr. Evans said that Exubera might have a harder time winning
insurance coverage, since it was merely a new form of an existing
treatment. Injectable insulin typically costs about $1,200 a year per
patient.
Patients with Type 2 diabetes slowly lose the ability to produce
insulin, a hormone secreted by the pancreas that controls the amount
of sugar in the blood, even as their bodies grow steadily more
resistant to the insulin they do make. The complications of late-
stage diabetes can be devastating, including blindness and amputations.
Current diabetes drugs work by lowering blood sugar, either by
sensitizing the body to insulin or by encouraging the pancreas to
make more insulin. But over time, the conventional therapies tend to
lose their effectiveness, and most patients must eventually inject
themselves with insulin. That is why the new drugs, with their new
approaches, are generating such interest.
Galvus, from the Swiss drug company Novartis, and Januvia, from
Merck, raise the levels of a naturally occurring hormone that is
released in the stomach and intestines during eating. The hormone,
called GLP-1, causes the pancreas to produce more insulin while
simultaneously discouraging the liver from producing sugar.
Both Galvus and Januvia, which are sometimes called gliptins, appear
to have few side effects and work well with existing diabetes drugs,
according to papers presented at the A.D.A. conference. While the
F.D.A. has still to finish its review of the drugs, they are almost
certain to be approved, Mr. Evans of Sanford Bernstein said. Doctors
are optimistic, too.
"They are another class of drugs that will help us," said Dr. Joel
Zonszein, the director of the clinical diabetes center at Montefiore
Medical Center in the Bronx. Dr. Zonszein said he had been paid in
the past to speak for Merck but has not been a consultant to it or
any other company.
Galvus and Januvia do not appear to be quite as potent at lowering
blood sugar as metformin, the existing first-line diabetes drug. But
because of their mild side effects, they will probably be given as an
adjunct to metformin, replacing an older group of diabetes drugs —
known as sulfonylureas — that are given to patients as a second- or
third-line treatment, Dr. Zonszein and other doctors said.
The sulfonylureas cause weight gain in many patients and have a high
risk of hypoglycemia, or low blood sugar, a potentially dangerous
condition that can occur when insulin levels rise too quickly.
Wall Street analysts are bullish about Galvus and Januvia, predicting
that each drug could have annual sales as high as $2 billion.
The fourth new drug is Exubera, Pfizer's inhalable insulin, which the
F.D.A. approved in January and Pfizer plans to begin marketing this
month. Insulin, the standard treatment for late-stage diabetes since
the 1920's, is the most potent method of controlling blood sugar and
is used by about five million Americans every day.
But until now it has been available only via injection. Pfizer argues
that Exubera will attract patients who should be taking insulin but
have not wanted to inject themselves.
"No other medicine can get all patients to their goals as insulin
can," said Dr. Michael Berelowitz, a senior vice president of Pfizer
who is an endocrinologist.
Still, some other doctors and analysts say that Exubera's benefits
have been overstated, especially because clinical trials have shown
that the drug slightly reduces patients' ability to breathe.
"Patient and doctor will have to weigh very carefully what the
benefit and the risk really is," Dr. Buse said.
The success of Byetta, meanwhile, has caused some doctors to question
whether diabetes patients fear injections as much as Pfizer claims.
Like insulin, Byetta must be injected. But unlike insulin, Byetta
causes significant weight loss in many patients and seems to pose
very little risk of causing hypoglycemia. Byetta's most common side
effect is nausea, which can be severe.
Eli Lilly and Amylin, which jointly manufacture Byetta, have not
advertised Byetta to consumers, instead marketing it directly to
doctors. Still, demand for the drug has soared since last year,
growing faster than either analysts or the companies had expected.
About 200,000 patients now take Byetta, the companies say, and
analysts expect sales of close to $400 million this year.
Meanwhile, the companies are testing a version of Byetta that would
need to be injected only once a week, instead of daily. If approved,
that drug, currently called exenatide LAR, will easily top $1 billion
in annual sales, analysts say.
Dr. Alan Garber, a professor of medicine at Baylor University, said
that patients do not mind injecting Byetta to benefit from its weight
loss effects. In addition, some animal studies appear to show that
Byetta may cause the pancreas to regrow beta cells, which produce
insulin, Dr. Garber said. Dr. Garber has not consulted for Lilly or
Amylin.
Dr. Dennis Kim, the senior director of medical affairs at Amylin,
said that his company and Lilly were working on studies to determine
whether Byetta could help pancreatic cells regenerate. But doing so
will be difficult, Dr. Kim said, because researchers cannot ethically
ask volunteers to undergo pancreatic biopsies.
"I'd love to have the data that conclusively shows that this has long-
term benefits on people's beta cell function and mass," he said. For
now, the theory remains unproved, he said.
Still, Dr. Garber, the Baylor professor, said he hoped that Byetta,
especially when given to patients with relatively early-stage
diabetes, might be able to halt the progression of the disease or
even reverse its course.
"That has the potential to fundamentally change the diabetes
paradigm," he said.
---------------------------------
James Love, CPTech / www.cptech.org / mailto:james.love@cptech.org /
tel. +1.202.332.2670 / mobile +1.202.361.3040
"If everyone thinks the same: No one thinks." Bill Walton